1Y Close · As of Aug 26, 2026
GL Pharm Tech operates in the Wholesale Trade sector.
Legal name: GL Pharm Tech Corp.
In fiscal year 2025, GL Pharm Tech (204840) reported revenue of 35.3 billion KRW, up 35.4% from 26.0 billion KRW a year earlier.
Operating profit was 268 million KRW and net income was 12 million KRW in the same year.
As of the Aug 26, 2026 close, the market capitalization was 70.9 billion KRW, with a P/B of 3.56.
These figures can be verified in the DART filing (receipt no. 20260318001300).
Financials
| Year | Rev | Op Inc | Net Inc |
|---|---|---|---|
| 2025 | 35.3B | 268M | 12M |
| 2024 | 26.0B | -1.8B | -2.3B |
| 2023 | 26.0B | -3.2B | -3.7B |
| 2022 | 16.7B | -3.3B | -790M |
| 2021 | 12.4B | -2.7B | -3.7B |
Recent Filings
Material Business Matters (Clinical Trial Decision)
Semi-Annual Report (2026.06)
Trading Halt Lifted (Reverse Split Re-listing)
Checks
1 of 8 checked items currently applicable.
Market Cap & Price: Market cap is above the delisting threshold.
Administrative Designation: No administrative designation criteria met.
Audit Opinion: Audit opinion: Unqualified (clean).
Convertible Bonds: No convertible bonds outstanding.
Capital Increase: No capital-increase filings in the last 180 days.
Treasury Stock: No treasury stock filings.
Embezzlement & Litigation: No embezzlement or litigation filings in the last 180 days.
Major Shareholder Change: No major shareholder changes in the last 180 days.
Recent Filings
| Date | Filing |
|---|---|
| 2026-08-21 | Material Business Matters (Clinical Trial Decision) |
| 2026-08-13 | Semi-Annual Report (2026.06) |
| 2026-08-10 | Trading Halt Lifted (Reverse Split Re-listing) |
| 2026-08-06 | Large Shareholding Report (General) |
| 2026-08-06 | Officer/Major Shareholder Ownership Report |